Genetic Variants of MicroRNA-146a and MicroRNA-196a2 are Associated with Poor Outcome but not Risk of High-Grade B-Cell Non-Hodgkin Lymphoma

Somaia M. Mousa 1, Hala Shiba 1, Sahar Kamal 1, Doaa S. Mahmoud 1, Wael A. Edesa 2

1 Clinical Pathology Department, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt; 2 Clinical Oncology Department, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt

Abstract

Background: Polymorphisms in microRNAs (miRNAs) encoding genes are involved in carcinogenesis. However, their relation to lymphomagenesis is still unclear.

Aim: To investigate the influence of miRNA-146a rs2910164 G/C polymorphism and miRNA-196a2 rs11614913 C/T polymorphism on risk and clinical outcome of high-grade B cell non-Hodgkin lymphoma (HGB-NHL).

Methods: Seventy-five patients with HGB-NHL and 100 matched controls were screened for miRNA-146a rs2910164 G/C and miRNA-196a2 rs11614913 C/T polymorphisms by Polymerase Chain Reaction-Restriction Fragment length Polymorphism (PCR-RFLP).

Results: The two studied miRNA polymorphisms were not associated with the risk of NHL. The GG genotype of miRNA-146a rs2910164 was associated with a worse disease-free survival (DFS) compared to the GC and CC genotypes (HR = 5.7; 95% CI = 1.05-31.09; p = 0.044). The miRNA-196a2 rs11614913 CC genotype was associated as well with worse DFS compared to the CT and TT genotypes (HR = 10.37; 95% CI = 1.80-59.62; p = 0.009). No significant association was found between the studied miRNA polymorphisms and patients' overall survival.

Conclusions: miRNA-146a rs2910164 G/C and miRNA-196a2 rs11614913 C/T polymorphisms may be associated with shorter DFS in HGB-NHL.

Keywords: High-grade non-Hodgkin lymphoma, miRNA-146a rs2910164, miRNA-196a2 rs11614913, Prognosis

Introduction

MicroRNAs (miRNAs) are endogenous short (21-24 nucleotides) single stranded non-protein coding RNA molecules that control gene expression at the posttranscriptional level. They bind either to the 3'-untranslated end of their target messenger RNA (mRNA) with subsequent translational repression or to the open reading frame resulting in mRNA degradation. Therefore, they are responsible of many physiological processes including cell proliferation, differentiation and apoptosis.

MiRNAs have specific expression patterns in different cancers and therefore they may be considered as non-invasive tumour markers for cancer diagnosis and prognosis. Single nucleotide polymorphisms (SNPs) in genes coding miRNAs may disrupt their expression and maturation and might be implicated in the process of carcinogenesis. MiRNA-146a rs2910164 G/C polymorphism and miRNA-196a2 rs11614913 C/T polymorphism have been found to be associated with susceptibility to a variety of solid tumours like colorectal cancer, stomach cancer, hepatocellular carcinoma, breast cancer and papillary thyroid carcinoma.
Little is known about the association between these miRNA gene polymorphisms and haematological malignancies like leukemia and lymphoma. B-cell non-Hodgkin lymphoma (B-NHL) is a genetically heterogeneous B-cell neoplasm in which molecular biomarkers have been widely used for diagnosis and prognosis \(^{14}\). Few studies have explored the association between miRNA-146a and miRNA-196a2 polymorphisms and NHL focusing mainly on disease susceptibility \(^{15-17}\). We performed this work to study the relation between miRNA-146a rs2910164 G/C polymorphism and miRNA-196a2 rs11614913 C/T polymorphism and risk of high-grade B-NHL and to identify their influence on disease outcome.

**Methods**

This single institution observational case-control study was conducted during the period from January 2017 through January 2019 at Kasr Al-Ainy School of Medicine, Cairo University, Egypt.

**Participants**

The study included 75 patients with high grade B-NHL and 100 age and sex matched healthy controls. Patients were enrolled in the study during their follow up visits at Kasr Al-Ainy Centre of Clinical Oncology and Nuclear Medicine (NEMROCK), Cairo University. Healthy controls were invited to participate in the study during their outpatient clinic visits at the New Kasr Al-Ainy Teaching Hospital for routine check-up provided that they have normal complete blood count.

**Management of non-Hodgkin lymphoma**

According to the world health organization (WHO) classification, the diagnosis and classification of NHL was based on histopathological examination and immunohistochemical (IHC) studies of lymph node biopsy \(^{18}\). Due to logistic reasons, BCL2 and c-myc were done in some patients by IHC to detect double expressor diffuse large B-cell lymphoma (DLBCL). All patients were evaluated by history and clinical examination. Laboratory work up included complete blood picture, renal and hepatic profile, serum uric acid, lactate dehydrogenase (LDH), bone marrow biopsy and screening for hepatitis B surface antigen. In addition to echocardiography, patients had computerized tomography (CT) with contrast of the chest, abdomen, and pelvis, positron emission tomography (PET/CT) was done if feasible. Clinical staging was assessed according to the Ann Arbor classification system \(^{19}\) and performance status (PS) was determined using the Eastern Cooperative Oncology Group (ECOG) Scale \(^{20}\). The International Prognostic Index (IPI) score was used to classify patients into low, low-intermediate, high-intermediate or high risk groups \(^{21}\). Patients were assessed clinically before each treatment cycle, by CT scan or PET/CT after 3 cycles and at the end of treatment plan. Assessment of response was performed according to Lugano criteria \(^{22}\).

Non-bulky early disease (stages I and II) received either R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone) for 3 cycles and involved field radiotherapy or 6 cycles of R-CHOP, while patients with bulky disease receive 6 cycles of R-CHOP and radiotherapy. Patients with advanced disease (stages III and IV) received 6 cycles of R-CHOP. R-EPOCH (rituximab plus etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin) regimen was used in patients with primary mediastinal large B-cell lymphoma and double expressor lymphoma.

**Genetic study**

Three mL of venous blood was collected on ethylene diamine tetra-acetic acid (EDTA) by sterile venepuncture using a sterile vacutainer tube. By using Gene JET Whole blood Genomic DNA purification Mini kit (Thermo Fisher Scientific, USA), genomic DNA was extracted from whole blood. Genotyping of miRNA-146a rs2910164 and miRNA-196a2 rs11614913 was performed by Polymerase Chain Reaction-Restriction Fragment length Polymorphism (PCR- RFLP) assay as described before \(^{12}\). The PCRs were done in a total volume of 25 µL containing 100 ng genomic DNA, 25 pM of each primer and 12.5 μL PCR master mix.

The PCR conditions comprised of an initial denaturation step at 94°C for 5 minutes followed by 30 cycles of denaturation at 94°C for 60 seconds, annealing at 62°C for miRNA-146a and 63°C for miRNA-196a2; for 60 seconds and extension at 72°C for 30 seconds and final extension at 72°C for 10 minutes. The presence of the PCR amplicon (147 bp for miRNA-146a and 149 bp for miRNA-196a2) was confirmed on 2% agarose gel electrophoresis. The PCR products were digested overnight at 37°C with the appropriate restriction enzyme (SacI for miRNA-146a and MspI for miRNA-196a2). Visualization of digested PCR products were performed on ethidium bromide stained 3% agarose gel electrophoresis.
**Statistical analyses**

Numerical data were presented as mean and standard deviation and compared by student’s t test, while qualitative data were described as number and percentage and compared by Chi-square / Fisher’s exact test. The SNP genotypes were grouped according to the dominant and recessive models. Disease-free survival (DFS) and overall survival (OS) were conducted using Kaplan-Meier method. DFS was calculated from date of complete remission till date of relapse. OS was calculated from the date of diagnosis to the date of death or the last follow up. Comparison between two survival curves was done using log rank test. Association between the genotypes of patients and survivals was estimated by univariate Cox regression analysis and results were expressed as hazard ratio (HR) with 95% confidence interval (CI). A p-value < 0.05 was considered significant.

Statistical analysis was performed using IBM SPSS® Statistics version 24 (IBM® Corp., Armonk, NY, USA).

**Results**

The study included 75 high grade B-NHL patients with a mean age of 48.89± 12.06 years. They were 32 males and 43 females. Clinicopathological characteristics of patients are shown in Table 1. The majority of patients (86.7%) were DLBCL. Other pathological subtypes include; 6 patients (8%) with T-cell rich B-cell lymphomas, 3 (4%) with mantle cell lymphomas and 1 (1.3%) with grade III follicular lymphoma. Based on their response to therapy, 61 (81.3%) patients achieved complete remission (CR), 1 (1.3%) showed partial remission (PR), 13 (17.3%) were refractory to therapy and 9 (12%) showed disease relapse during follow up.

Genotype and allele frequencies of miRNA-146a and miRNA-196a2 polymorphisms among patients and control groups are shown in Table 2.

Polymorphisms in miRNA-146a and miRNA-196a2 were not found to be associated with risk of high-grade B-NHL among the studied patients. Furthermore, no statistical differences were encountered when patients were stratified by histological subtype, B symptoms, bone marrow involvement, clinical stage, PS, IPI and LDH level (Tables 3 and 4).

At the time of analysis (June 2020), the estimated DFS was 92.5% at 1 year, and 71.4% at 3 years for a median follow up of 13.5 months. The GG genotype of miRNA-146a rs2910164 was associated with a worse DFS compared to the GC and CC genotypes (HR =5.7; 95% CI=1.05-31.09; p=0.044) in the recessive model (GG vs GC/CC) (Figure 1, Table 5).

Likewise, the miRNA-196a2 rs11614913 CC genotype was associated with worse DFS compared to the CT and TT genotypes (HR=10.37; 95% CI=1.80-59.62; p = 0.009) in the recessive model (CC vs CT/TT), (Figure 2, Table 5). The estimated OS at 1 year was 91% and at 3 years was 70%. No statistically significant difference was demonstrated between miRNA-146a and miRNA-196a2 genotypes and OS among the studied patients (Table 6).

---

**Table 1: Characteristics of 75 patients with non-Hodgkin lymphoma**

| Characteristic                  | n (%)   |
|--------------------------------|---------|
| **Histological subtype**       |         |
| DLBCL                          | 65 (86.7)|
| Others                         | 10 (13.3)|
| **B symptoms**                 |         |
| Yes                            | 43 (57.3)|
| No                             | 32 (42.7)|
| **Bone marrow involvement**    |         |
| Yes                            | 17 (22.7)|
| No                             | 58 (77.3)|
| **Clinical stage**             |         |
| Early (I/II)                   | 33 (44) |
| Late (III/IV)                  | 42 (56) |
| **ECOG performance status**    |         |
| <2                             | 49 (65.3)|
| ≥ 2                            | 26 (34.7)|
| **IPI risk group**             |         |
| Low / Low-intermediate         | 50 (66.7)|
| High-intermediate / High       | 25 (33.3)|
| **Lactate dehydrogenase**      |         |
| Normal                         | 14 (18.7)|
| Elevated                       | 61 (81.3)|

DLBCL: Diffuse large B-cell lymphoma, ECOG: Eastern Cooperative Oncology Group, IPI: International Prognostic Index
Table 2: Genotype and allele frequencies of miRNA-146a and miRNA-196a2 in patients with B-NHL and control subjects

| miRNA  | Genotypes | Genotypes | Genotypes | Genotypes | Genotypes | Genotypes | Genotypes | Genotypes |
|--------|------------|------------|------------|------------|------------|------------|------------|------------|
|        | GG         | GC         | CC         | Allele G   | Allele C   | GG & GC    | CC         |
|        | n (%)      | n (%)      | n (%)      | n (%)      | n (%)      | n (%)      | n (%)      |
| miRNA-146a | GG 27 (36) | GC 39 (52) | CC 9 (12)  | 93 (62)    | 57 (38)    | 66 (88)    | 9 (12)     |
|         | GC 32 (32) | GC 60 (60) | CC 8 (8)   | 124 (62)   | 76 (38)    | 92 (92)    | 8 (8)      |
|         | GG 0.498   | GC 1       | CC 1       | GG 0.629   | GC & CC 0  | GG & GC 0  | CC 1       |
|         | GG 0.498   | GC 0.498   | CC 1       | GG 0.629   | GC & CC 0  | GG & GC 0  | CC 1       |
| miRNA-196a2 | CC 30 (40) | CT 34 (45.3) | TT 11 (14.7) | 94 (62.7) | 56 (37.3) | 94 (62.7) | 56 (37.3) |
|         | CT 36 (36) | CT 57 (57) | TT 7 (7)   | 129 (64.5) | 71 (35.5) | 129 (64.5) | 71 (35.5) |
|         | CC 0.153   | CC 0.73    | TT 0.73    | CC 0.637   | CC & CT 0.131 | CC & CT 0.131 | TT 0.73    |
|         | CC 0.153   | CC 0.73    | TT 0.73    | CC 0.637   | CC & CT 0.131 | CC & CT 0.131 | TT 0.73    |

Discussion

Growing evidence revealed the association between SNP in genes encoding miRNA and susceptibility of different types of cancer particularly stomach, colorectal and breast cancers. MiRNAs that are frequently associated with cancers are: miRNA-146a, miRNA-196a-2 and miRNA-149. Some miRNA genes polymorphisms were linked to poor disease outcome like worse overall survival of patients with stomach and lung cancers, high rate of recurrence in colorectal adenocarcinoma patients and unfavourable recurrence free survival in Chinese patients with colorectal cancer.

Few data are available about the association between miRNA gene polymorphisms and NHL. The present study investigated the association between miRNA-146a rs2910164 G/C polymorphism and miRNA-196a2 rs11614913 C/T polymorphisms and susceptibility and outcome of high-grade B-NHL among Egyptian patients. We found that polymorphisms in miRNA-146a and miRNA-196a2 were not associated with risk of high-grade B-NHL. In agreement with our study, these polymorphisms were not associated with susceptibility to acquired immune deficiency syndrome (AIDS) associated NHL in a previous multicentre study. In contrast to our findings, the CC genotype of miRNA-146a rs2910164 polymorphism was found to be associated with risk of DLBCL in Chinese Han population. Likewise, the CC/CT genotypes of miRNA-196a2 were associated with lymphoma risk in a cohort of B/T-NHL patients of Chinese Han origin.

As for disease outcome, our results show for the first time an association between the GG genotype of miRNA-146a rs2910164 and the CC genotype of miRNA-196a2 rs11614913 and worse DFS. A systematic review and meta-analysis investigated the prognostic role of miRNA polymorphisms in cancers other than NHL showed that the CC genotype of miRNA-196a2 rs11614913 is associated with a worse DFS. However, the GG genotype of miRNA-146a rs2910164 is associated with better DFS. These results were contrary to our results regarding miRNA-146a polymorphism but consistent with our findings for miRNA-196a2 polymorphism. Similar results were observed for OS (but not DFS) in another meta-analysis that also did not include NHL studies. This discrepancy may be the result of different types of cancers studied and different populations included (most of them are Asian). The expression level of miRNAs is not the same in cancer and normal cells and even it varies among different types of cancer. This may explain the role of SNPs in genes coding miRNAs in cancer pathogenesis.
Table 3: The relationship between miRNA-146a polymorphism and the clinicopathological characteristics of patients

| Characteristic                  | GG (n=27) | GC & CC (n=48) | p value | CC (n=9) | GC & GG (n=66) | p value |
|--------------------------------|-----------|----------------|---------|----------|----------------|---------|
| Histological subtype           |           |                |         |          |                |         |
| DLBCL                           | 24 (88.9) | 41 (85.4)      | 1       | 8 (88.9) | 57 (86.4)      | 1       |
| Others                          | 3 (11.1)  | 7 (14.6)       |         | 1 (11.1) | 9 (13.6)       |         |
| B symptoms                      |           |                |         |          |                |         |
| Yes                             | 18 (66.7) | 25 (47.9)      | 0.237   | 8 (88.9) | 35 (53)        | 0.069   |
| No                              | 9 (33.3)  | 23 (52.1)      |         | 1 (11.1) | 31 (47.0)      |         |
| Bone marrow involvement         |           |                |         |          |                |         |
| Yes                             | 5 (18.5)  | 12 (25)        | 0.579   | 3 (33.3) | 14 (21.2)      | 0.674   |
| No                              | 22 (81.5) | 36 (75)        |         | 6 (66.7) | 52 (78.8)      |         |
| Clinical stage                  |           |                |         |          |                |         |
| Early (I / II)                  | 13 (48.1) | 20 (41.7)      | 0.634   | 3 (33.3) | 30 (45.5)      | 0.723   |
| Late (III/IV)                   | 14 (51.9) | 28 (58.3)      |         | 6 (66.7) | 36 (54.5)      |         |
| ECOG performance status         |           |                |         |          |                |         |
| <2                              | 18 (66.7) | 31 (64.6)      | 1       | 4 (44.4) | 45 (68.2)      | 0.261   |
| ≥2                              | 9 (33.3)  | 17 (35.4)      |         | 5 (55.6) | 21 (31.8)      |         |
| IPI risk group                  |           |                |         |          |                |         |
| Low / Low-intermediate          | 17 (63)   | 33 (68.8)      | 0.799   | 4 (44.4) | 46 (69.7)      | 0.261   |
| High-intermediate / High        | 10 (17.0) | 15 (31.2)      |         | 5 (55.6) | 20 (30.3)      |         |
| Lactate dehydrogenase           |           |                |         |          |                |         |
| Normal                          | 5 (18.5)  | 9 (18.8)       | 1       | 2 (22.2) | 12 (18.2)      | 1       |
| Elevated                        | 22 (81.5) | 39 (81.2)      |         | 7 (77.8) | 54 (81.8)      |         |

DLBCL: Diffuse large B-cell lymphoma, ECOG: Eastern Cooperative Oncology Group, IPI: International prognostic index

Table 4: The relationship between miRNA-196a2 polymorphism and the clinicopathological characteristics of patients

| Characteristic                  | CC (n=30) | CT & TT (n=45) | p value | TT (n=11) | CT & CC (n=64) | p value |
|--------------------------------|-----------|----------------|---------|----------|----------------|---------|
| Histological subtype           |           |                |         |          |                |         |
| DLBCL                           | 25 (83.3) | 40 (88.9)      | 0.508   | 10 (90.9) | 55 (85.9)      | 1       |
| Others                          | 5 (16.7)  | 5 (33.3)       |         | 1 (9.1)  | 9 (14.1)       |         |
| B symptoms                      |           |                |         |          |                |         |
| Yes                             | 15 (50)   | 28 (62.2)      | 0.345   | 8 (72.7)  | 35 (54.7)      | 0.335   |
| No                              | 15 (50)   | 17 (37.8)      |         | 3 (27.3)  | 29 (45.3)      |         |
| Bone marrow involvement         |           |                |         |          |                |         |
| Yes                             | 5 (16.7)  | 12 (26.7)      | 0.403   | 4 (36.4)  | 13 (20.3)      | 0.257   |
| No                              | 25 (83.3) | 33 (73.3)      |         | 7 (63.6)  | 51 (79.7)      |         |
| Clinical stage                  |           |                |         |          |                |         |
| Early (I / II)                  | 11 (36.7) | 22 (48.9)      | 0.347   | 5 (45.5)  | 28 (43.8)      | 1       |
| Late (III/IV)                   | 19 (63.3) | 23 (51.1)      |         | 6 (54.5)  | 36 (56.2)      |         |
| ECOG performance status         |           |                |         |          |                |         |
| <2                              | 22 (73.3) | 27 (60)        | 0.323   | 5 (45.5)  | 44 (68.8)      | 0.174   |
| ≥2                              | 8 (26.7)  | 18 (40)        |         | 6 (54.5)  | 20 (31.2)      |         |
| IPI risk group                  |           |                |         |          |                |         |
| Low / Low-intermediate          | 19 (63.3) | 31 (73.4)      | 0.803   | 5 (45.5)  | 45 (70.3)      | 0.164   |
| High-intermediate / High        | 11 (36.7) | 14 (26.6)      |         | 6 (54.5)  | 19 (29.7)      |         |
| Lactate dehydrogenase           |           |                |         |          |                |         |
| Normal                          | 5 (16.7)  | 9 (20)         | 0.772   | 0         | 14 (21.9)      | 0.112   |
| Elevated                        | 25 (83.3) | 36 (80.0)      |         | 11 (100)  | 50 (78.1)      |         |

DLBCL: Diffuse large B-cell lymphoma, ECOG: Eastern Cooperative Oncology Group, IPI: International prognostic index
Table 5: Relationship between miRNA-146a and miRNA-196a2 polymorphisms and disease-free survival

| Polymorphisms | No. of patients | No. of relapses | Cumulative survival (%) | p value |
|---------------|-----------------|-----------------|-------------------------|---------|
|               |                 |                 | At 12 months | At 36 months |         |
| miRNA-146a    |                 |                 |             |             |         |
| GG            | 23              | 4               | 90.9        | 72.7        | 0.044   |
| GC & CC       | 38              | 5               | 93.5        | 71.7        |         |
| miRNA-146a    |                 |                 |             |             |         |
| GG & GC       | 54              | 9               | 91.7        | 68.9        | 0.395   |
| CC            | 7               | 0               | 100         | NR          |         |
| miRNA-196a2   |                 |                 |             |             |         |
| CC            | 24              | 5               | 88          | NR          | 0.009   |
| CT & TT       | 37              | 4               | 96.3        | 88.3        |         |
| miRNA-196a2   |                 |                 |             |             |         |
| CC & CT       | 51              | 8               | 93.9        | 70.9        | 0.659   |
| TT            | 10              | 1               | 83.3        | 83.3        |         |

NR: Not reached

Figure 1: Kaplan-Meier curves for disease-free survival (DFS) according to miRNA-146a rs2910164 genotypes

Figure 2: Kaplan-Meier curves for disease-free survival (DFS) according to miRNA-196a2 rs11614913 genotypes
Table 6: Relationship between miRNA-146a and miRNA-196a2 polymorphisms and overall survival

| Polymorphisms     | No. of patients | No. of events | Cumulative survival (%) | p value |
|-------------------|-----------------|---------------|-------------------------|---------|
|                   |                 |               | At 12 months | At 36 months |         |
| miRNA-146a        |                 |               |             |             |         |
| GG                | 27              | 3             | 93.5        | 77.9        | 0.152   |
| GC & CC           | 48              | 1             | 97.5        | 97.5        |         |
| miRNA-146a        |                 |               |             |             |         |
| GG & GC           | 66              | 3             | 96.8        | 91.9        | 0.319   |
| CC                | 9               | 1             | 88.9        | 88.9        |         |
| miRNA-196a2       |                 |               |             |             |         |
| CC                | 30              | 1             | 83.3        | 83.3        | 0.587   |
| CT & TT           | 45              | 3             | 92.9        | 92.9        |         |
| miRNA-196a2       |                 |               |             |             |         |
| CC & CT           | 64              | 3             | 96.7        | 91.9        | 0.356   |
| TT                | 11              | 1             | 90          | 90          |         |

The G allele of miRNA-146a rs2910164 was found to be associated with increased miRNA-146a expression. Upregulation of miRNA-146a was detected in DLBCL cases suggesting a role of this polymorphism in pathogenesis of DLBCL. The CC/CT genotypes of miRNA-196a2 rs11614913 were found to be associated with indicators of poor NHL prognosis like advanced stage, bone marrow invasion, and B symptoms. This was attributed to higher expression of miRNA-196a2 that was detected among patients carrying the C allele of miRNA-196a2 rs11614913.

Conclusions
The results of the current study provide initial evidence that miRNA-146a and miRNA-196a2 polymorphisms may have a negative impact on NHL prognosis. Further larger scale studies are warranted to validate our findings.

Acknowledgments
Not applicable.

Authors’ contribution
Conception or design: SMM, HS, SK, WE; Acquisition, analysis or interpretation of data: DSM, SMM, WE; Drafting or revising the manuscript: SMM, HS, SK, DSM, WE; Approval of the manuscript version to be published: All authors; Agreement to be accountable for all aspects of the work: All authors.

Conflict of interest
The authors declare that they have no conflict of interest to disclose.

Data availability
The deidentified datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethical considerations
The study was approved by the Research Committees of Kasr Al-Ainy Center of Clinical Oncology and Nuclear Medicine and the Clinical and Chemical Pathology Department, Faculty of Medicine, Cairo University. Patients and controls signed an informed consent before beginning of the study.

Funding
The authors received institutional funding from the Faculty of Medicine, Cairo University.

Study registration
Not applicable.

References
1. Wienholds E, Plasterk RH. MicroRNA function in animal development. FEBS Lett. 2005; 579(26):5911-5922.
2. Verghese ET, Hanby AM, Speirs V, Hughes TA. Small is beautiful: microRNAs and breast cancer-where are we now? J Pathol. 2008; 215(3):214-221.
3. Cheng AM, Byrom MW, Shelton J, Ford LP. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res. 2005; 33(4):1290-1297.
4. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006; 6(11):857-866.
5. Pipan V, Zorc M, Kunej T. MicroRNA polymorphisms in cancer: A literature analysis. Cancers (Basel). 2015; 7(3): 1806-1814.
6. Chae YS, Kim JG, Lee SJ, et al. A miR-146a polymorphism (rs2910164) predicts risk of and survival from colorectal cancer. Anticancer Res. 2013; 33(8): 3233-3239.
7. Zhu L, Chu H, Gu D, et al. A functional polymorphism in miRNA-196a2 is associated with colorectal cancer risk in a Chinese population. DNA Cell Biol. 2012; 31(3): 350-354.
8. Xu Z, Zhang L, Cao H, Bai B. MiR-146a rs2910164 GC polymorphism and gastric cancer susceptibility: a meta-analysis. BMC Med Genet. 2014; 15:117.
9. Peng S, Kuang Z, Sheng C, Zhang Y, Xu H, Cheng Q. Association of microRNA-196a-2 gene polymorphism with gastric cancer risk in a Chinese population. Dig Dis Sci. 2010; 55(8): 2288-2293.
10. Xu T, Zhu Y, Wei QK, et al. A functional polymorphism in the miR-146a gene is associated with the risk for hepatocellular carcinoma. Carcinogenesis. 2008; 29(11): 2126-2131.

11. Akkiz H, Bayram S, Bekar A, Akgölü E, Ulger Y. A functional polymorphism in pre-microRNA-196a-2 contributes to the susceptibility to hepatocellular carcinoma in a Turkish population: a case-control study. J Viral Hepat. 2011; 18(7): e399-407.

12. Bodal VK, Sangwan S, Bal MS, Kaur M, Sharma S, Kaur B. Association between microRNA 146a and microRNA 196a2 genes polymorphism and breast cancer risk in north Indian women. Asian Pac J Cancer Prev. 2017; 18(9): 2345-2348.

13. Jazdzewski K, Murray EL, Franssila K, Jarzab B, Schoenberg DR, de la Chapelle A. Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci U S A. 2008; 105(20): 7269-7274.

14. Onaindia A, Medeiros LJ, Patel KP. Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms. Mod Pathol. 2017; 30(10): 1338-1366.

15. Zhuang H, Shen J, Zheng Z, Luo X, Gao R, Zhuang X. MicroRNA-146a rs2910164 polymorphism and the risk of diffuse large B cell lymphoma in the Chinese Han population. Med Oncol. 2014; 31(12): 306.

16. Li T, Niu L, Wu L, et al. A functional polymorphism in microRNA-196a2 is associated with increased susceptibility to non-Hodgkin lymphoma. Tumour Biol. 2015; 36(5): 3279-3284.

17. Peckham-Gregory EC, Thapa DR, Martinson J, et al. MicroRNA-related polymorphisms and non-Hodgkin lymphoma susceptibility in the Multicenter AIDS Cohort Study. Cancer Epidemiol. 2016; 45: 47-57.

18. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127(20): 2375-2390.

19. Armitage JO. Staging non-Hodgkin lymphoma. CA Cancer J Clin. 2005; 55(6):368-376.

20. Oken MM, Creech RH, Torrney DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5(6): 649-655.

21. International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993; 329(14): 987-994.

22. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32(27): 3059-3068.

23. Xia L, Ren Y, Fang X, et al. Prognostic role of common microRNA polymorphisms in cancers: evidence from a meta-analysis. PLoS One. 2014; 9(10): e106799.

24. Lin M, Gu J, Eng C, et al. Genetic polymorphisms in MicroRNA-related genes as predictors of clinical outcomes in colorectal adenocarcinoma patients. Clin Cancer Res. 2012; 18(14): 3982-3991.

25. Xing J, Wan S, Zhou F, et al. Genetic polymorphisms in pre-microRNA genes as prognostic markers of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2012; 21(1): 217-227.

26. Ding HX, Lv Z, Yuan Y, Xu Q. MiRNA polymorphisms and cancer prognosis: A systematic review and meta-analysis. Front Oncol. 2018; 8: 596.